Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Sanofi
Woman and Man
Between 18 years
and 99 years
Sanofi
Update Il y a 5 ans
Étude TED13751 : étude de phase 1-2, évaluant la tolérance, la pharmacocinétique et l'activité anti tumorale de SAR408701, chez des patients ayant une tumeur solide avancée.
L’objectif de cette étude est d’évaluer la tolérance, la pharmacocinétique et l'activité anti tumorale de SAR408701, chez des patients ayant une tumeur solide avancée. Cette étude comprendra deux par...
Country
France
organs
Tumeurs solides
,
Côlon ou Rectum (colorectal)
,
Poumon, type non à petites cellules
,
Estomac
Specialty
Immunothérapie - Vaccinothérapie
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Sanofi-Synthelabo Recherche
Update Il y a 5 ans
Effect of a single oral 120 µg dose of SSR150106XB compared to placebo on the assessment of post dental surgical pain after extraction of an impacted or partially impacted third molar in 90 male and female patients – Randomized, double-blind, placebo- controlled, parallel-group study –
To assess the effect of a single oral 120 µg dose of SSR150106XB on the intensity of post dental surgery pain as compared to placebo.
Country
None
organs
None
Specialty
None
unknown
More information
Woman
Between 18 years
and 99 years
Sanofi
Update Il y a 5 ans
Étude TED14856 : étude de phase 1-2 évaluant la sécurité, l'efficacité, la pharmacocinétique et la pharmacodynamique du SAR439859, soit en monothérapie, soit associé à du palbociclib, chez des femmes ménopausées ayant un cancer du sein de stade avancé avec des récepteurs positifs aux oestrogènes. [Informations issues du site clinicaltrials.gov et traduites par l'INCa]
Le cancer du sein est une tumeur maligne qui se développe à partir des cellules normales du sein. La maladie peut survenir à tout âge avec une moyenne autour de 60 ans. Le cancer du sein peut envahir ...
Country
France
organs
Sein
Specialty
Thérapies Ciblées
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Sanofi aventis US Inc
Update Il y a 5 ans
A 13-week Multinational, Randomized, Double-Blind, Placebo-Controlled, Dose-Response Trial Assessing the Safety, Tolerability and Efficacy of AVE0010 in Metformin-Treated Subjects with Type 2 Diabetes Mellitus
The primary objective of the study is to evaluate the dose-response relationship of AVE0010 administered once daily and twice daily with chronic dosing in metformin-treated subjects with type 2 diabet...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi Pasteur SA
Update Il y a 5 ans
Safety of the Inactivated, Split-Virion Influenza Vaccine Administered by the Intradermal Route in Healthy Children
To describe the safety of the 9µg formulation of the inactivated, split-virion influenza vaccine administered by the intradermal (ID) route in children aged 6 to 35 months and 3 to 8 years.
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Sanofi Pasteur MSD S.N.C
Update Il y a 5 ans
A study to compare immune response of V503 to Gardasil in 16- to 26-year-old men
The primary objective is to demonstrate that administration of the 9vHPVvaccine induces non-inferior Geometric Mean Titres (GMTs) for serum anti-HPV 6, 11, 16, and 18, compared to GARDASIL® in 16- to ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi-aventis
Update Il y a 5 ans
An open-label, randomized, two-arm parallel group study to compare the effects of 4-week QD treatment with lixisenatide or liraglutide on the postprandial plasma glucose in patients with type 2 diabetes not adequately controlled with metformin
To investigate the effects of repeated subcutaneous doses of 20 µg lixisenatide as compared to 1.8 mg liraglutide in reducing postprandial plasma glucose (PPG) assessed as area under the plasma glucos...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 16 years
and 99 years
Sanofi
Update Il y a 5 ans
EFC11603 / MYRALL : Essai de phase 2 évaluant le SAR3419, un anticorps monoclonal anti-CD19 conjugué à la maytansine, administré en monothérapie, chez des patients ayant une leucémie aiguë lymphoblastique (LAL) en rechute ou réfractaire. [essai clos aux inclusions]
L’objectif de cet essai est d’évaluer l’efficacité et la tolérance du SAR3419, chez des patients ayant une leucémie aiguë lymphoblastique (LAL) en rechute ou réfractaire. Cette étude comporte 2 parti...
Country
France
organs
Leucémies aiguës
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Sanofi-Aventis Groupe
Update Il y a 5 ans
Effect of insulin glulisine compared to insulin aspart and insulin lispro when administered by Continuous Subcutaneous Insulin Infusion (CSII) on specific pump parameters in patient with Type 1 Diabetes Mellitus
To assess the superiority of insulin glulisine over insulin aspart and insulin lispro administered by external pump in term of unexplained hyperglycemia and/or infusion set occlusion. For the purpose...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Genzyme, a Sanofi Company
Update Il y a 5 ans
A trial of antigen-specific immune tolerance induction in mucopolysaccharidosis I (MPS I) patients initiating enzyme replacement therapy with Aldurazyme® (laronidase)
To evaluate the antibody response to Aldurazyme in newly treated severe MPS I patients following an antigen-specific immunosuppressive regimen.
Country
None
organs
None
Specialty
None
More information
Previous
12
13
14
15
16
17
18
19
20
21
Next